Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma

The combination of temsirolimus (TEM), an MTOR inhibitor, and hydroxychloroquine (HCQ), an autophagy inhibitor, augments cell death in preclinical models. This phase 1 dose-escalation study evaluated the maximum tolerated dose (MTD), safety, preliminary activity, pharmacokinetics, and pharmacodynami...

Descripción completa

Detalles Bibliográficos
Autores principales: Rangwala, Reshma, Chang, Yunyoung C, Hu, Janice, Algazy, Kenneth M, Evans, Tracey L, Fecher, Leslie A, Schuchter, Lynn M, Torigian, Drew A, Panosian, Jeffrey T, Troxel, Andrea B, Tan, Kay-See, Heitjan, Daniel F, DeMichele, Angela M, Vaughn, David J, Redlinger, Maryann, Alavi, Abass, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, O’Dwyer, Peter J, Amaravadi, Ravi K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203516/
https://www.ncbi.nlm.nih.gov/pubmed/24991838
http://dx.doi.org/10.4161/auto.29119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4203516/
https://www.ncbi.nlm.nih.gov/pubmed/24991838
http://dx.doi.org/10.4161/auto.29119

Ejemplares similares